Skip to content

Public FDA record

Z-1883-2011: Access Immunoassay Systems enhanced AccuTnl Reagent Kit, Part Number: A78803 The Access Accu Tri assay i

Recall record Z-1883-2011 for Beckman Coulter Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-1883-2011
Company in FDA record
Beckman Coulter Inc.
FDA classification date
Apr 4, 2011
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 17, 2026
Recall classification
Unknown — no matched enforcement classification

Reason stated in the source

The recall was initiated after Beckman Coulter confirmed that under certain circumstances, the following assays may produce elevated values at the low end when run in conjunction with the enhanced Access Accu Tnl assay (P/N A 78033): (1) Access Total BhCG (P/N 33500); (2) Access HYPERsensitive hTSH/Fast hTSH (P/N 33820); (3) Access hFSH (P/N 33520). The issue can occur only when the assays are

Source facts

Action
The firm, Beckman Coulter, sent an "URGENT: PRODUCT CORRECTIVE ACTION" letter dated December 16, 2009 to all customers. The letter described the product, problem and actions to be taken. Beckman Coulter instructed the customers to do the following mitigation to reduce the risk of encountering an erroneous result: Systems with multiple reagent pipettors (UniCel Dxl 800 and 600; UniCel DxC 880i, 860i, 680i, and 660i): 1. Designate enhanced Access AccuTnl to a different reagent pipettor (s) than Access Total BhCG/Dil-hCG2, hTSH/Fast hTSH and hFSH. 2. Discard any open Access Total BhCG, hTSH/Fast hTSH and hFSH reagent packs 3. Calibrate Access Total BhCG, hTSH and hFSH using fresh reagent packs 4. Run QC following acceptable calibration curves. Proceed with operation following acceptable QC performance Systems without multiple reagent pipettors (Access, Access 2; SYNCHRON LXi 725, UniCel DxC 600i): 1. Discard any open Access Total BhCG, hTSH/Fast hTSH and hFSH reagent packs. 2. Calibrate Access Total BhCG, hTSH/Fast hTSH and hFSH using fresh reagent packs 3. Run QC following acceptable calibration curves. Ensure that controls and patient samples for Access Total BhCG/Dil-hCG2, hTSH/Fast hTSH and hFSH are not run immediately following enhanced Access AccuTnl controls or patient samples. For example, during routine QC runs, ensure that these assays are requested prior to enhanced Access AccuTnl. 4. Proceed with operation following acceptable QC performance. NOTE: An enhanced AccuTnl sample loaded with a system priority of STAT will interrupt routine Total BhCG/Dil-hCG2, hTSH/Fast hTSH and hFSH sample aspiration. Avoid loading enhanced AccuTnl sample aspiration. Avoid loading enhanced AccuTnl samples with a system priority of STAT during aspiration of Total BhCG/Dil-hCG2, hTSH/Fast hTSH and hFSH. Diagnostic test results should be interpreted in light of the clinical presentation of the patient, including: symptoms, clinical history, data from other
Initiated
2009-12-10
Root cause
Other
Terminated
2012-05-07
Distribution
Worldwide distribution: USA and country of Canada.
Recall number
Z-1883-2011
Recall status
Terminated
CDRH record ID
91134
FDA classified
2011-04-04
Recall event number
55554

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗